A Phase I safety and pharmacodynamic activity trial shows IMC-M113V, the first soluble T cell receptor (TCR) therapy for people living with HIV, is well tolerated. Immunocore presented the findings at the Conference on Retroviruses and Opportunistic Infection (CROI). The bispecific soluble TCR therapy built on the company’s ImmTAX technology which is being developed for […]
